McKesson Corp (MCK) KPIs and segments
Close on Nov 18, 2026Market cap $126.43BP/E 29.0Yield 0.29%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của McKesson · năm tài chính kết thúc ngày 31 tháng 3
Nhìn nhanh KPI của McKesson: 36 chỉ số vận hành, trong đó có GLP-1 Medications Distribution Revenue, U.S. Pharmaceutical Primary Distribution Centers và Health Mart Independent Pharmacies in U.S. Franchise, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của McKesson kết thúc ngày 31 tháng 3 — Q1 FY27 = CQ2 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
U.S. Pharmaceutical($M) | 89,954 | 83,166 | 87,110 | 85,726 | 71,715 | 68,790 | 73,023 | 69,766 | |||||
North American Pharmaceutical($M) | 86,773 | 79,120 | 88,322 | 86,481 | 82,729 | 76,943 | 81,198 | 80,018 | |||||
Oncology & Multispecialty($M) | 14,222 | 12,711 | 13,010 | 12,044 | 10,658 | 9,431 | 9,493 | 9,157 | |||||
International($M) | 3,738 | 3,461 | 3,860 | 3,709 | 3,691 | 3,548 | 3,639 | 3,475 | |||||
Medical-Surgical Solutions($M) | 2,819 | 2,868 | 2,991 | 2,947 | 2,701 | 2,853 | 2,949 | 2,946 | 2,636 | 2,833 | 3,031 | 2,834 | |
Prescription Technology Solutions($M) | 1,566 | 1,495 | 1,500 | 1,376 | 1,434 | 1,339 | 1,371 | 1,265 | 1,241 | 1,180 | 1,205 | 1,140 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Prescription Technology Solutions($M) | 0 | -2 | -1 | 0 | -1 | -1 | -3 | -3 | -4 | ||||
International($M) | -13 | -25 | |||||||||||
Oncology & Multispecialty($M) | -18 | -14 | -17 | -23 | -24 | -24 | -27 | -19 | |||||
Medical-Surgical Solutions($M) | -27 | -13 | -24 | -32 | -25 | -34 | -36 | -42 | -51 | ||||
North American Pharmaceutical($M) | -64 | -115 | -84 | -74 | -61 | -85 | -62 | -66 | |||||
U.S. Pharmaceutical($M) | -73 | -28 | |||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4 | |||||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4 | |||||||||||||
GLP-1 Medications Distribution Revenue ($M)($M)2 | 15,000 | 14,000 | 14,000 | 13,200 | 12,100 | 10,900 | 10,900 | 10,400 | 8,800 | 7,500 | |||
GLP-1 Distribution Revenue YoY Growth (%)(%) | 24.0% | 22.0% | 26.0% | 24.0% | 38.0% | 46.0% | 45.0% | 47.0% | 26.0% | 24.0% | |||
GLP-1 Distribution Revenue YoY Dollar Increase ($M)($M) | 3,000 | 2,000 | 3,000 | 2,600 | 3,300 | 3,500 | 3,400 | 3,300 | 1,800 | 1,500 | |||
GLP-1 Distribution Revenue Sequential QoQ Growth (Disclosed in Selected Quarters Only; Missing Q2 FY26)(%) | 13.0% | -4.0% | 7.0% | 6.0% | 11.0% | 17.0% | |||||||
North American Pharmaceutical — Segment Revenue ($M)($M)8 | 86,773 | 79,120 | 88,322 | 86,481 | 82,729 | 76,943 | 81,198 | 80,018 | 66,348 | ||||
North American Pharmaceutical — GAAP Operating Profit/(Loss) ($M)($M) | 903 | 1,157 | 1,055 | 852 | 594 | 1,152 | 744 | 347 | 702 | ||||
North American Pharmaceutical — Non-GAAP Adjusted Operating Profit ($M)($M) | 894 | 980 | 872 | 851 | 749 | 885 | 822 | 754 | 684 | ||||
North American Pharmaceutical — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M) | -9 | -177 | -183 | -1 | 155 | -267 | 78 | 407 | -18 | ||||
North American Pharmaceutical — GAAP Operating Profit Margin (%)(%) | 1.0% | 1.5% | 1.2% | 1.0% | 0.7% | 1.5% | 0.9% | 0.4% | 1.1% | ||||
North American Pharmaceutical — Non-GAAP Adjusted Operating Profit Margin (%)(%) | 1.0% | 1.2% | 1.0% | 1.0% | 0.9% | 1.2% | 1.0% | 0.9% | 1.0% | ||||
North American Pharmaceutical — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M) | 85,870 | 77,963 | 87,267 | 85,629 | 82,135 | 75,791 | 80,454 | 79,671 | 65,646 | ||||
North American Pharmaceutical — Segment Depreciation & Amortization ($M)($M) | 39 | 36 | 34 | 32 | 32 | 31 | 33 | 43 | 48 | ||||
North American Pharmaceutical — Segment Expenditures for Long-Lived Assets ($M)($M) | 64 | 115 | 84 | 74 | 61 | 85 | 62 | 66 | 30 | ||||
Oncology & Multispecialty — Segment Revenue ($M)($M)8 | 14,222 | 12,711 | 13,010 | 12,044 | 10,658 | 9,431 | 9,493 | 9,157 | 8,781 | ||||
Oncology & Multispecialty — GAAP Operating Profit/(Loss) ($M)($M) | 325 | 301 | 304 | 332 | 212 | 217 | 202 | 200 | 148 | ||||
Oncology & Multispecialty — Non-GAAP Adjusted Operating Profit ($M)($M) | 405 | 385 | 366 | 397 | 287 | 252 | 233 | 232 | 219 | ||||
Oncology & Multispecialty — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M) | 80 | 84 | 62 | 65 | 75 | 35 | 31 | 32 | 71 | ||||
Oncology & Multispecialty — GAAP Operating Profit Margin (%)(%) | 2.3% | 2.4% | 2.3% | 2.8% | 2.0% | 2.3% | 2.1% | 2.2% | 1.7% | ||||
Oncology & Multispecialty — Non-GAAP Adjusted Operating Profit Margin (%)(%) | 2.9% | 3.0% | 2.8% | 3.3% | 2.7% | 2.7% | 2.5% | 2.5% | 2.5% | ||||
Oncology & Multispecialty — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M) | 13,897 | 12,410 | 12,706 | 11,712 | 10,446 | 9,214 | 9,291 | 8,957 | 8,633 | ||||
Oncology & Multispecialty — Segment Depreciation & Amortization ($M)($M) | 66 | 64 | 63 | 71 | 42 | 36 | 37 | 37 | 38 | ||||
Oncology & Multispecialty — Segment Expenditures for Long-Lived Assets ($M)($M) | 18 | 14 | 17 | 23 | 24 | 24 | 27 | 19 | 18 | ||||
Prescription Technology Solutions (RxTS) — Segment Revenue ($M)($M)7 | 1,566 | 1,495 | 1,500 | 1,376 | 1,434 | 1,339 | 1,371 | 1,265 | 1,241 | 1,180 | 1,205 | 1,140 | |
Prescription Technology Solutions (RxTS) — Non-GAAP Adjusted Operating Profit ($M)($M) | 303 | 322 | 277 | 261 | 269 | 285 | 235 | 218 | 223 | 212 | 193 | 209 | |
Prescription Technology Solutions (RxTS) — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M) | 77 | 36 | 16 | 17 | 16 | 37 | 16 | 13 | 20 | 24 | 15 | -29 | |
Prescription Technology Solutions (RxTS) — GAAP Operating Profit Margin (%)(%) | 14.4% | 19.1% | 17.4% | 17.7% | 17.6% | 18.5% | 16.0% | 16.2% | 16.4% | 15.9% | 14.8% | 20.9% | |
Prescription Technology Solutions (RxTS) — Non-GAAP Adjusted Operating Profit Margin (%)(%) | 19.4% | 21.5% | 18.5% | 19.0% | 18.8% | 21.3% | 17.1% | 17.2% | 18.0% | 18.0% | 16.0% | 18.3% | |
Prescription Technology Solutions (RxTS) — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M) | 1,340 | 1,209 | 1,239 | 1,132 | 1,181 | 1,091 | 1,152 | 1,060 | 1,038 | ||||
Prescription Technology Solutions (RxTS) — Segment Depreciation & Amortization ($M)($M) | 19 | 20 | 21 | 20 | 21 | 21 | 22 | 22 | 21 | ||||
Prescription Technology Solutions (RxTS) — Segment Expenditures for Long-Lived Assets ($M)($M) | 0 | 2 | 1 | 0 | 1 | 1 | 3 | 3 | 4 | ||||
Medical-Surgical Solutions — Segment Revenue ($M)($M)7 | 2,819 | 2,868 | 2,991 | 2,947 | 2,701 | 2,853 | 2,949 | 2,946 | 2,632 | 2,837 | 3,031 | 2,834 | |
Medical-Surgical Solutions — Non-GAAP Adjusted Operating Profit ($M)($M) | 195 | 271 | 265 | 249 | 244 | 285 | 294 | 243 | 200 | 248 | 282 | 254 | |
Medical-Surgical Solutions — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M) | 73 | 39 | 0 | 29 | 23 | 58 | 25 | 152 | 8 | 35 | 14 | 10 | |
Medical-Surgical Solutions — GAAP Operating Profit Margin (%)(%) | 4.3% | 8.1% | 8.9% | 7.5% | 8.2% | 8.0% | 9.1% | 3.1% | 7.3% | 7.5% | 8.8% | 8.6% | |
Medical-Surgical Solutions — Non-GAAP Adjusted Operating Profit Margin (%)(%) | 6.9% | 9.5% | 8.9% | 8.5% | 9.0% | 10.0% | 10.0% | 8.3% | 7.6% | 8.7% | 9.3% | 9.0% | |
Medical-Surgical Solutions — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M) | 2,697 | 2,636 | 2,726 | 2,727 | 2,480 | 2,626 | 2,680 | 2,855 | 2,448 | ||||
Medical-Surgical Solutions — Segment Depreciation & Amortization ($M)($M) | 26 | 25 | 26 | 23 | 22 | 24 | 23 | 22 | 23 | ||||
Medical-Surgical Solutions — Segment Expenditures for Long-Lived Assets ($M)($M) | 27 | 13 | 24 | 32 | 25 | 34 | 36 | 42 | 51 | ||||
Other (Remaining International / Norwegian Operations) — Segment Revenue ($M)($M)8 | 0 | 101 | 335 | 302 | 305 | 257 | 283 | 265 | 281 | ||||
Other (Remaining International / Norwegian Operations) — GAAP Operating Profit/(Loss) ($M)($M) | 0 | 518 | 31 | 28 | 13 | 10 | 14 | 13 | 17 | ||||
Other (Remaining International / Norwegian Operations) — Non-GAAP Adjusted Operating Profit ($M)($M) | 0 | 8 | 28 | 25 | 13 | 9 | 11 | 14 | 14 | ||||
Other (Remaining International / Norwegian Operations) — Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M) | 0 | -510 | -3 | -3 | 0 | -1 | -3 | 1 | -3 | ||||
Other (Remaining International / Norwegian Operations) — GAAP Operating Profit Margin (%)(%) | 0.0% | 512.9% | 9.3% | 9.3% | 4.3% | 3.9% | 5.0% | 4.9% | 6.1% | ||||
Other (Remaining International / Norwegian Operations) — Non-GAAP Adjusted Operating Profit Margin (%)(%) | 0.0% | 7.9% | 8.4% | 8.3% | 4.3% | 3.5% | 3.9% | 5.3% | 5.0% | ||||
Other (Remaining International / Norwegian Operations) — Other Segment Expense, Net (ASU 2023-07 Significant Expense, $M)($M) | 0 | -417 | 304 | 274 | 292 | 247 | 269 | 252 | 264 | ||||
Other (Remaining International / Norwegian Operations) — Segment Depreciation & Amortization ($M)($M) | 0 | 0 | 0 | 1 | 3 | 4 | 4 | 5 | 5 | ||||
Other (Remaining International / Norwegian Operations) — Segment Expenditures for Long-Lived Assets ($M)($M) | 0 | 1 | 4 | 4 | 1 | 5 | 3 | 4 | 5 | ||||
Total Reportable Segments & Other — GAAP Operating Profit ($M)($M)5 | 1,576 | 2,494 | 1,916 | 1,676 | 1,293 | 1,854 | 1,448 | 856 | 1,262 | 1,530 | 879 | 1,141 | |
Total Reportable Segments & Other — Non-GAAP Adjusted Operating Profit ($M)($M) | 1,797 | 1,966 | 1,808 | 1,783 | 1,562 | 1,716 | 1,595 | 1,461 | 1,340 | 1,455 | 1,408 | 1,367 | |
Corporate Expenses, Net — GAAP ($M)($M) | -191 | -308 | -223 | -207 | -193 | -294 | -155 | -244 | -103 | -280 | -203 | -164 | |
Corporate Expenses, Net — Non-GAAP Adjusted ($M)($M) | -144 | -209 | -156 | -151 | -138 | -157 | -132 | -170 | -35 | -193 | -147 | -159 | |
Corporate — Depreciation & Amortization ($M)($M) | 45 | 51 | 44 | 41 | 37 | 35 | 34 | 34 | 35 | ||||
Corporate — Expenditures for Long-Lived Assets ($M)($M) | 43 | 40 | 45 | 63 | 77 | 129 | 65 | 84 | 59 | ||||
U.S. Pharmaceutical (Legacy Segment Pre-Q2 FY26 Reorg) — Revenue ($M)($M)3 | 89,954 | 83,166 | 87,110 | 85,726 | 71,715 | 68,790 | 73,023 | 69,766 | |||||
International (Legacy Segment Pre-Q2 FY26 Reorg) — Revenue ($M)($M)3 | 3,738 | 3,461 | 3,860 | 3,709 | 3,691 | 3,548 | 3,639 | 3,475 | |||||
McKesson Ventures Equity Investments Pre-Tax Net Gains/(Losses) ($M)($M) | -15 | 11 | 3 | 1 | 6 | -15 | 110 | -8 | -10 | ||||
Non-GAAP Adjusted Earnings ($M)($M)7 | 1,183 | 1,434 | 1,155 | 1,227 | 1,037 | 1,274 | 1,016 | 915 | 1,029 | 813 | 1,032 | 841 | |
Non-GAAP Adjusted Diluted EPS ($/Share)($) | 9.93 | 11.69 | 9.34 | 9.86 | 8.26 | 10.12 | 8.03 | 7.07 | 7.88 | 6.18 | 7.74 | 6.23 | |
Non-GAAP Adjusted Gross Profit ($M)($M) | 3,677 | 3,862 | 3,662 | 3,534 | 3,264 | 3,388 | 3,342 | 3,246 | 3,060 | 3,315 | 3,131 | 3,045 | |
Non-GAAP Adjusted Operating Expenses ($M)($M) | -2,090 | -2,141 | -2,084 | -1,964 | -1,904 | -1,885 | -1,948 | -1,989 | -1,927 | -2,087 | -1,904 | -1,863 | |
Consolidated Non-GAAP Adjusted Operating Profit (Adjusted EBIT, $M)($M) | 1,653 | 1,757 | 1,652 | 1,632 | 1,424 | 1,559 | 1,463 | 1,291 | 1,305 | 1,262 | 1,261 | 1,208 | |
Consolidated GAAP Operating Profit (Income from Continuing Operations Before Interest & Taxes, $M)($M) | 1,385 | 2,186 | 1,693 | 1,469 | 1,100 | 1,560 | 1,293 | 612 | 1,159 | 1,250 | 676 | 977 | |
Non-GAAP Adjusted Interest Expense ($M)($M) | -75 | -59 | -59 | -68 | -44 | -40 | -62 | -72 | -70 | -75 | -58 | -55 | |
Non-GAAP Adjusted Income Tax Expense ($M)($M) | -340 | -206 | -366 | -273 | -295 | -197 | -335 | -256 | -160 | -334 | -127 | -271 | |
Total Pre-Tax Non-GAAP Adjustments to Operating Profit ($M)($M)6 | 268 | -429 | -41 | 163 | 324 | -1 | 170 | 679 | 146 | 12 | 585 | 231 | |
Amortization of Acquisition-Related Intangibles (Pre-Tax Adjustment, $M)($M) | 74 | 73 | 73 | 80 | 50 | 50 | 53 | 60 | 63 | 63 | 62 | 62 | |
Transaction-Related Expenses & Adjustments (Pre-Tax Adjustment, $M)($M) | 2 | 2 | 4 | 6 | 5 | 5 | 5 | 6 | 5 | 5 | 6 | 6 | |
LIFO Inventory-Related Credits/(Charges) (Pre-Tax Adjustment, $M)($M) | -2 | -182 | -10 | -11 | -7 | -3 | 89 | -2 | -2 | -246 | 2 | 55 | |
Gains from Antitrust Legal Settlements (Pre-Tax Adjustment, $M)($M) | -6 | 0 | -15 | 0 | -8 | -260 | -31 | -63 | -90 | -24 | -23 | -79 | |
Restructuring, Impairment & Related Charges, Net (Pre-Tax Adjustment, $M)($M) | 136 | 99 | 36 | 63 | 47 | 73 | 32 | 171 | 10 | 31 | 4 | 28 | |
Claims & Litigation Charges, Net (Opioid & Related Settlements, Pre-Tax Adjustment, $M)($M) | -34 | -1 | 0 | -2 | 0 | 0 | 0 | -4 | 112 | 149 | 0 | -2 | |
Non-GAAP Free Cash Flow ($M)($M)2 | -372 | 3,236 | 1,057 | 2,224 | -1,107 | 7,470 | -2,579 | 1,882 | -1,547 | 3,878 | 100 | 825 | |
Payments for Property, Plant & Equipment (Schedule 6 FCF Reconciliation, $M)($M) | 112 | 111 | 108 | 106 | 111 | 169 | 126 | 136 | 106 | 188 | 90 | 75 | |
Capitalized Software Expenditures ($M)($M) | 40 | 74 | 67 | 90 | 78 | 109 | 70 | 82 | 61 | 81 | 64 | 65 | |
Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share)($)3 | 44.20 | 43.80 | 38.80 | 38.35 | 37.10 | 36.75 | 32.55 | 32.40 | 31.75 | 31.25 | 27.25 | 26.80 | |
Full-Year Guidance: Adjusted Diluted EPS — High End ($/Share)($) | 45 | 44.60 | 39.20 | 38.85 | 37.90 | 37.55 | 32.95 | 33 | 32.55 | 32.05 | 27.65 | 27.40 | |
Full-Year Guidance: Non-GAAP Free Cash Flow — Low End ($M)($M) | 4,500 | 4,500 | 4,400 | 4,400 | 4,400 | 4,400 | 4,800 | 4,800 | 4,800 | 4,800 | 3,700 | ||
Full-Year Guidance: Non-GAAP Free Cash Flow — High End ($M)($M) | 4,900 | 4,900 | 4,800 | 4,800 | 4,800 | 4,800 | 5,200 | 5,200 | 5,200 | 5,200 | 4,100 | ||
Total Opioid-Related Settlement Liabilities on Balance Sheet ($M)($M)3 | 5,660 | 5,692 | 5,708 | 5,720 | 6,377 | 6,377 | 6,392 | 6,392 | 6,892 | 6,778 | 6,644 | 6,644 | |
Current Opioid Litigation Liabilities (Within Accrued Expenses, $M)($M) | 602 | 601 | 605 | 617 | 776 | 776 | 775 | 775 | 778 | 665 | 516 | 516 | |
Long-Term Opioid Litigation Liabilities ($M)($M) | 5,058 | 5,091 | 5,103 | 5,103 | 5,601 | 5,601 | 5,617 | 5,617 | 6,114 | 6,113 | 6,128 | 6,128 | |
Total Noncurrent Litigation Reserve (XBRL LossContingencyAccrualCarryingValueNoncurrent, $M)($M) | 5,058 | 5,091 | 5,103 | 5,103 | 5,601 | 5,601 | 5,617 | 5,617 | 6,114 | 6,113 | 6,128 | 6,128 | |
LIFO Inventory Valuation Reserve ($M)2 | |||||||||||||
Restructuring Liability Reserve Balance ($M)($M) | 74 | 44 | 35 | 70 | 88 | 126 | 157 | 188 | 43 | 55 | 54 | 66 | |
Restructuring, Impairment & Related Charges (GAAP Note 4, $M)($M) | 136 | 36 | 63 | 47 | 32 | 234 | 10 | 4 | 28 | ||||
Consolidated Long-Lived Assets, Net (Geographic Footnote Total, $M)($M)2 | 3,429 | 3,432 | 3,380 | 3,357 | 3,282 | 3,183 | 2,811 | ||||||
United States Long-Lived Assets, Net ($M)($M) | 3,185 | 3,177 | 3,126 | 3,096 | 2,952 | 2,877 | 2,477 | ||||||
Foreign / International Long-Lived Assets, Net ($M)($M) | 244 | 255 | 254 | 261 | 330 | 306 | 334 | ||||||
Operating Lease Right-of-Use (ROU) Assets ($M)($M)2 | 1,941 | 2,058 | 2,056 | 1,991 | 2,168 | 1,782 | 1,758 | 1,495 | 1,735 | 1,729 | 1,679 | 1,680 | |
Operating Lease Liabilities — Current ($M)($M) | 292 | 287 | 286 | 278 | 297 | 258 | 256 | 243 | 296 | 295 | 296 | 296 | |
Operating Lease Liabilities — Noncurrent ($M)($M) | 1,680 | 1,801 | 1,781 | 1,756 | 1,859 | 1,478 | 1,489 | 1,232 | 1,466 | 1,466 | 1,421 | 1,436 | |
Remaining Share Repurchase Authorization ($M)($M)2 | 5,175 | 2,719 | 5,381 | 6,070 | 6,879 | 7,469 | 7,739 | 8,560 | 6,088 | 6,615 | 7,300 | 8,100 | |
Total Shares Repurchased in Quarter (Open Market + ASR + Tax Withholding, Millions)(M) | 3.60 | 2.50 | 0.80 | 1.20 | 0.80 | 0.50 | 1.50 | 2.90 | 1 | 1.30 | 1.90 | 2 | |
Common Stock Repurchased Value (XBRL StockRepurchasedDuringPeriodValue, $M)($M) | 2,569 | 696 | 817 | 592 | 821 | 1,529 | 528 | 868 | 840 | ||||
U.S. Federal Government Prime Contract Obligations to McKesson ($M)($M) | 3,879 | 3,404 | 3,851 | 3,499 | 3,198 | 2,515 | 2,727 | 2,264 | 2,136 | 2,135 | 1,737 | 2,157 | |
Peer Benchmark: Cencora, Inc. (COR) — Consolidated Revenue ($M)($M)3 | 84,755 | 78,356 | 85,932 | 80,664 | 75,454 | 81,487 | 74,241 | 68,414 | 72,253 | ||||
Cencora (COR) — GAAP Operating Income ($M)($M) | 1,120 | 1,143 | 760 | 868 | 1,036 | 706 | 673 | 553 | 823 | ||||
Cencora (COR) — GAAP Net Income ($M)($M) | 764 | 1,641 | 560 | 687 | 718 | 489 | 484 | 421 | 602 | ||||
Cencora (COR) — Merchandise Inventories ($M)($M) | 21,030 | 20,010 | 24,079 | 20,493 | 20,138 | 18,966 | 20,508 | 18,999 | 18,302 | 17,631 | 18,652 | 17,455 | |
Peer Benchmark: Cardinal Health, Inc. (CAH) — Consolidated Revenue ($M)($M)3 | 65,627 | 64,009 | 54,878 | 55,264 | 52,277 | 54,868 | 57,442 | 54,650 | |||||
Cardinal Health (CAH) — GAAP Operating Income/(Loss) ($M)($M) | 707 | 668 | 730 | 549 | 568 | 369 | 505 | -32 | |||||
Cardinal Health (CAH) — GAAP Net Income/(Loss) ($M)($M) | 467 | 450 | 506 | 400 | 416 | 261 | 368 | -12 | |||||
Cardinal Health (CAH) — Merchandise Inventories ($M)($M) | 17,297 | 20,116 | 17,559 | 16,831 | 16,158 | 16,904 | 15,619 | 14,957 | 17,277 | 18,451 | 16,987 | ||
Peer Benchmark: Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M)($M)3 | 1,442 | 1,351 | 1,435 | 1,416 | 1,333 | 1,279 | 1,227 | 1,146 | 1,093 | ||||
Consolidated Revenue (GAAP, $M)($M)18 | 105,380 | 96,295 | 106,158 | 103,150 | 97,827 | 90,823 | 95,294 | 93,651 | 79,283 | 76,355 | 80,898 | 77,215 | |
Cost of Sales (GAAP, $M)($M) | 101,695 | 92,251 | 102,473 | 99,608 | 94,548 | 87,184 | 92,010 | 90,403 | 76,131 | 72,770 | 77,746 | 74,146 | |
Gross Profit (GAAP, $M)($M) | 3,685 | 4,044 | 3,685 | 3,542 | 3,279 | 3,639 | 3,284 | 3,248 | 3,152 | 3,585 | 3,152 | 3,069 | |
Total Operating Expenses (GAAP, $M)($M) | 2,366 | 1,894 | 2,066 | 2,135 | 2,243 | 2,048 | 2,060 | 2,670 | 2,123 | 2,369 | 2,510 | 2,118 | |
Selling, Distribution & Administrative Expenses (GAAP, $M)($M) | 2,264 | 1,796 | 2,030 | 2,074 | 2,196 | 1,975 | 2,028 | 2,503 | 2,001 | 2,189 | 2,506 | 2,092 | |
Restructuring, Impairment & Related Charges (GAAP Income Statement, $M)($M) | 136 | 99 | 36 | 63 | 47 | 68 | 32 | 234 | 10 | 31 | 4 | 28 | |
Claims & Litigation Settlement Charges (GAAP, $M)($M) | 34 | 1 | 0 | 2 | 0 | 0 | 0 | 4 | -112 | -149 | 0 | 2 | |
Operating Income (GAAP, $M)($M) | 1,319 | 2,150 | 1,619 | 1,407 | 1,036 | 1,591 | 1,224 | 578 | 1,029 | 1,216 | 642 | 951 | |
Interest Expense (GAAP, $M)($M) | 77 | 61 | 63 | 74 | 49 | 45 | 67 | 78 | 75 | 80 | 64 | 61 | |
Income from Continuing Operations Before Income Taxes (GAAP, $M)($M) | 1,308 | 2,125 | 1,630 | 1,395 | 1,051 | 1,515 | 1,226 | 534 | 1,084 | 1,170 | 612 | 916 | |
Income Tax Expense/(Benefit) (GAAP, $M)($M) | 276 | 270 | 380 | 232 | 220 | 209 | 298 | 247 | 124 | 340 | -18 | 213 | |
Net Income/(Loss) Including Noncontrolling Interests (GAAP, $M)($M) | 1,032 | 1,855 | 1,250 | 1,163 | 831 | 1,306 | 928 | 287 | 960 | 830 | 630 | 703 | |
Net Income Attributable to Noncontrolling Interests (GAAP, $M)($M) | 418 | 173 | 64 | 53 | 47 | 46 | 49 | 46 | 45 | 39 | 41 | 39 | |
Net Income/(Loss) Attributable to McKesson Corporation (GAAP, $M)($M) | 614 | 1,682 | 1,186 | 1,110 | 784 | 1,260 | 879 | 241 | 915 | 791 | 589 | 664 | |
Diluted Earnings/(Loss) Per Common Share (GAAP, $/Share)($) | 5.15 | 9.59 | 8.92 | 6.25 | 6.95 | 1.87 | 7 | 4.42 | 4.92 | ||||
Basic Earnings/(Loss) Per Common Share (GAAP, $/Share)($) | 5.17 | 9.63 | 8.95 | 6.28 | 6.98 | 1.88 | 7.04 | 4.45 | 4.95 | ||||
Dividends Declared Per Common Share ($/Share)($) | 0.82 | 0.82 | 0.82 | 0.82 | 0.71 | 0.71 | 0.71 | 0.71 | 0.62 | 0.62 | 0.62 | 0.62 | |
Diluted Weighted-Average Common Shares (Millions)(M) | 119 | 124 | 124 | 126 | 127 | 129 | 131 | 133 | 135 | ||||
Basic Weighted-Average Common Shares (Millions)(M) | 119 | 123 | 124 | 125 | 126 | 129 | 130 | 133 | 134 | ||||
Total Assets (GAAP, $M)($M)18 | 88,330 | 82,323 | 84,190 | 84,160 | 81,311 | 75,140 | 71,081 | 72,429 | 71,670 | 67,443 | 66,512 | 66,091 | |
Cash & Cash Equivalents ($M)($M) | 5,164 | 3,975 | 2,959 | 4,004 | 2,418 | 5,956 | 1,131 | 2,509 | 2,302 | 4,583 | 1,982 | 2,524 | |
Receivables, Net ($M)($M) | 30,316 | 27,985 | 28,213 | 28,286 | 28,158 | 25,643 | 25,831 | 25,270 | 23,743 | 21,622 | 23,066 | 22,494 | |
Inventories, Net ($M)($M) | 26,259 | 24,207 | 27,067 | 26,134 | 25,065 | 23,001 | 23,837 | 24,176 | 25,571 | 21,139 | 22,020 | 21,945 | |
Prepaid Expenses & Other Current Assets ($M)($M) | 1,098 | 1,043 | 1,458 | 1,463 | 1,160 | 1,063 | 942 | 751 | 636 | 626 | 572 | 568 | |
Total Current Assets ($M)($M) | 62,837 | 57,210 | 59,697 | 59,887 | 56,801 | 55,398 | 51,741 | 53,341 | 52,252 | 47,970 | 47,640 | 47,531 | |
Property, Plant & Equipment, Net ($M)($M) | 2,684 | 2,668 | 2,634 | 2,627 | 2,574 | 2,502 | 2,397 | 2,361 | 2,357 | 2,316 | 2,201 | 2,171 | |
Goodwill ($M)($M) | 11,278 | 11,316 | 11,324 | 11,283 | 11,365 | 10,022 | 10,004 | 10,087 | 10,118 | 10,132 | 9,973 | 9,934 | |
Intangible Assets, Net ($M)($M) | 4,013 | 4,079 | 4,179 | 4,220 | 4,272 | 1,464 | 1,509 | 1,573 | 2,045 | 2,110 | 2,097 | 2,142 | |
Other Noncurrent Assets ($M)($M) | 5,577 | 4,992 | 4,300 | 4,152 | 4,131 | 3,972 | 3,672 | 3,572 | 3,163 | 3,186 | 2,922 | 2,633 | |
Drafts & Accounts Payable ($M)($M) | 63,731 | 59,973 | 60,683 | 60,938 | 57,861 | 55,330 | 49,689 | 53,317 | 51,704 | 47,097 | 46,699 | 46,795 | |
Accrued Expenses & Other Current Liabilities ($M)($M) | 5,036 | 5,490 | 6,030 | 5,068 | 4,924 | 4,825 | 5,027 | 4,787 | 4,383 | 4,915 | 4,400 | 4,007 | |
Total Current Liabilities ($M)($M) | 70,356 | 67,017 | 68,131 | 68,031 | 64,331 | 61,604 | 58,562 | 58,771 | 56,434 | 52,357 | 51,661 | 51,147 | |
Long-Term Debt ($M)($M) | 8,432 | 5,259 | 5,425 | 6,011 | 6,528 | 4,463 | 4,422 | 5,691 | 5,584 | 5,579 | 5,625 | 5,535 | |
Long-Term Litigation & Other Noncurrent Liabilities ($M)($M) | 2,742 | 2,659 | 2,741 | 2,751 | 2,868 | 2,659 | 2,603 | 2,712 | 2,525 | 2,610 | 2,381 | 2,197 | |
Retained Earnings ($M)($M) | 22,808 | 22,291 | 20,710 | 19,622 | 18,616 | 17,921 | 16,752 | 15,959 | 15,810 | 14,978 | 14,268 | 13,761 | |
Treasury Shares, at Cost ($M)($M) | -34,890 | -32,005 | -29,654 | -28,955 | -28,137 | -27,439 | -27,141 | -26,310 | -24,781 | -24,119 | -23,474 | -22,604 | |
McKesson Corporation Stockholders' Deficit/Equity ($M)($M) | -4,240 | -2,172 | -1,298 | -1,739 | -1,967 | -2,074 | -3,084 | -3,017 | -1,755 | -1,971 | -2,053 | -1,828 | |
Total Deficit/Equity Including Noncontrolling Interests ($M)($M) | -3,864 | -1,777 | -901 | -1,355 | -1,588 | -1,694 | -2,704 | -2,642 | -1,381 | -1,599 | -1,682 | -1,464 | |
Operating Cash Flow (GAAP, $M)($M)13 | -220 | 3,421 | 1,232 | 2,420 | -918 | 7,748 | -2,383 | 2,100 | -1,380 | 4,147 | 254 | 965 | |
Depreciation & Amortization (Cash Flow Statement, $M)($M) | 195 | -246 | 188 | 188 | 157 | -213 | 153 | 163 | 169 | ||||
Changes in Receivables ($M)($M) | -2,374 | 131 | 166 | -207 | -2,089 | 129 | -565 | -1,398 | -2,101 | 1,344 | -1,091 | -827 | |
Changes in Inventories ($M)($M) | -2,074 | 3,016 | -899 | -1,228 | -1,971 | 864 | 176 | 1,132 | -4,442 | 1,090 | -35 | -1,523 | |
Changes in Drafts & Accounts Payable ($M)($M) | 3,773 | -574 | -279 | 3,223 | 1,947 | 5,624 | -3,544 | 1,605 | 4,616 | 424 | -144 | 2,834 | |
Additions to Property, Plant & Equipment (GAAP CapEx, $M)($M) | 112 | 111 | 108 | 106 | 111 | 169 | 126 | 136 | 106 | 188 | 90 | 75 | |
Acquisitions, Net of Cash & Cash Equivalents Acquired ($M)($M) | -23 | -4 | -23 | -30 | -3,359 | -21 | -2 | -1 | 0 | -266 | -6 | 0 | |
Net Cash Used in Investing Activities (GAAP, $M)($M) | -214 | 425 | -269 | -24 | -3,564 | -224 | -136 | -286 | -87 | -577 | -180 | -166 | |
Proceeds from Issuances of Long-Term Debt ($M)($M) | 3,215 | 0 | 0 | 0 | 1,990 | 0 | 0 | 498 | 0 | 0 | 0 | 0 | |
Repayments of Long-Term Debt ($M)($M) | -1 | -8 | -1,197 | -2 | 0 | -9 | -9 | -501 | 0 | -8 | -9 | -3 | |
Common Stock Repurchases (Cash Outflow, $M)($M) | 2,530 | 2,671 | 680 | 818 | 581 | 300 | 827 | 1,492 | 527 | 678 | 842 | 809 | |
Dividends Paid ($M)($M) | 102 | 101 | 101 | 89 | 90 | 91 | 92 | 80 | 82 | 82 | 83 | 75 | |
Net Cash Used in Financing Activities (GAAP, $M)($M) | 1,632 | -2,820 | -2,026 | -961 | 1,176 | -2,855 | 1,298 | -1,599 | -809 | -968 | -622 | -909 | |
Net Change in Cash, Cash Equivalents & Restricted Cash ($M)($M) | 1,188 | 1,015 | -1,056 | 1,426 | -3,273 | 4,674 | -1,229 | 207 | -2,281 | 2,602 | -541 | -113 | |
31 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core operational KPIs — GLP-1 Medications Distribution Revenue ($15,000M in Q1 FY27, +23% YoY; $53,000M in FY26, +27% YoY; $41,000M in FY25 across 10 consecutive quarters FY2024Q4–FY2027Q1), U.S. Pharmaceutical Primary Distribution Centers (28) & Strategic Redistribution Centers (2), Health Mart Independent Franchise Pharmacies (3,900 in the U.S.) & McKesson Canada Banner Pharmacies (1,700), and Prescription Technology Solutions (RxTS) Prevented Abandoned Prescriptions (12.0 million in FY26) — are extracted from McKesson Form 10-K Item 1 and Quarterly Earnings Call Transcripts.
- Complete realigned 4-segment operating performance (North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions, and Other/Corporate) across 9 quarters (FY2025Q1–FY2027Q1) and 3 fiscal years (FY2024–FY2026), including GAAP Operating Profit, Non-GAAP Adjusted Operating Profit, GAAP & Non-GAAP Operating Profit Margins, ASU 2023-07 Significant Segment Operating Expenses (`Other segment expense, net`), Segment Depreciation & Amortization, and Segment Capital Expenditures, plus 25–30 quarters of pre-reorganization history for U.S. Pharmaceutical and International.
- Consolidated Non-GAAP reconciliation series (Adjusted Earnings, Adjusted Diluted EPS, Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted EBIT, Pre-Tax Adjustments Breakdown for Intangible Amortization, Transaction Expenses, LIFO Credits/Charges, Antitrust Settlement Gains, Restructuring, and Opioid/Litigation Claims) and Schedule 6 Non-GAAP Free Cash Flow & Capitalized Software Expenditures are compiled across 26–29 quarters through Q1 FY27, alongside Full-Year Guidance Evolution and the 2025 Investor Day 6-Year Non-GAAP Track Record.
- Only directly reported point figures and cumulative year-to-date period splits (`quarter = year-to-date − previous year-to-date` and `Q4 = full year − nine months` on cash flow and segment expense tables) are included; no self-computed ratios, margins, or growth rates are added. Consolidated-minus-standalone parent subtraction is not applicable because McKesson Corporation files consolidated US GAAP financial statements on Form 10-K without standalone parent-company operating revenue.
- Metrics that switched from exact point disclosures to approximate bounds in recent periods (The US Oncology Network provider count >3,300 / >3,400 in Q2/Q4 FY26 & Q1 FY27; worldwide total headcount >43,000 in FY26; RxTS annual patient savings 'over $9B / over $10B' in FY22–FY25) are excluded from active series and documented in `excluded`.
Không hiện vì thiếu các kỳ gần đây (15)
- Core Operational KPIs › U.S. Strategic Redistribution Centers Total Square Footage — Disclosed only as bound 'over 2.4 million square feet' across FY2020–FY2026 Form 10-K filings
- Core Operational KPIs › RxTS Connected Pharmacies & Providers Network — Disclosed only as bounds ('50,000+ pharmacies', '950,000+ providers') in 2025 Investor Day Presentation
- Oncology & Multispecialty › Sarah Cannon Research Institute (SCRI) Clinical Trials & Accruals — Disclosed only as cumulative bounds ('850+ first-in-human trials', '300+ FDA approvals', 'over 1,000 clinical trials') in 2025 Investor Day & 10-K
- Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › The US Oncology Network Providers (Disclosed Exact Points Only; Switched to >3,300 / >3,400 Bounds in Q2/Q4 FY26 & Q1 FY27)
- Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › The US Oncology Network Sites of Care (Disclosed Exact Points Only; Switched to >700 Bound in Q2 FY26)
- Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › The US Oncology Network States Covered (Not Disclosed in Q2 FY26–Q1 FY27)
- Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale › RxTS Annual Patient Medication Savings (Only FY2026 Disclosed as Exact $10B; FY2022–FY2025 Disclosed as Bounds 'over $9B / over $10B')
- Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Non-GAAP Adjusted Earnings ($M) › Non-GAAP Adjusted Other Income, Net ($M)
- Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Corporate Expenses — Low End ($M)
- Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Corporate Expenses — High End ($M)
- Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Interest Expense — Low End ($M)
- Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution › Full-Year Guidance: Adjusted Diluted EPS — Low End ($/Share) › Full-Year Guidance: Adjusted Interest Expense — High End ($M)
- Customer & Supplier Concentration, Workforce, Opioid Liabilities, LIFO, Leases & Share Repurchases › Total Employees Worldwide (Disclosed as Bound 'more than 43,000' in FY2026; Exact 45,000–80,000 in FY2020–FY2025)
- Customer & Supplier Concentration, Workforce, Opioid Liabilities, LIFO, Leases & Share Repurchases › LIFO Inventory Valuation Reserve ($M) › Effect of LIFO Inventory Liquidation / Period Charge ($M)
- Consolidated GAAP Financial Statements & XBRL Segment Baseline › Segment Baseline (XBRL): North American Pharmaceutical Revenue ($M) › Segment Baseline (XBRL): Other / International Revenue ($M)
Dữ liệu cập nhật 2026-11-03.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core Operational KPIs: GLP-1 Distribution, Pharmacy & DC Network & RxTS Scale
- GLP-1 Medications Distribution Revenue ($M) ($M)10 kỳ
- U.S. Pharmaceutical Primary Distribution Centers (Count)7 kỳ
- Health Mart Independent Pharmacies in U.S. Franchise Network (Count)6 kỳ
- RxTS Prevented Abandoned Prescriptions (Millions) (M)4 kỳ
- GLP-1 Distribution Revenue Sequential QoQ Growth (Disclosed in Selected Quarters Only; Missing Q2 FY26) (%)6 kỳ
Realigned 4-Segment Operating Performance (GAAP, Non-GAAP Adjusted & ASU 2023-07 Disclosures)
- North American Pharmaceutical — Segment Revenue ($M) ($M)9 kỳ
- Oncology & Multispecialty — Segment Revenue ($M) ($M)9 kỳ
- Prescription Technology Solutions (RxTS) — Segment Revenue ($M) ($M)28 kỳ
- Medical-Surgical Solutions — Segment Revenue ($M) ($M)30 kỳ
- Other (Remaining International / Norwegian Operations) — Segment Revenue ($M) ($M)9 kỳ
- Total Reportable Segments & Other — GAAP Operating Profit ($M) ($M)30 kỳ
- U.S. Pharmaceutical (Legacy Segment Pre-Q2 FY26 Reorg) — Revenue ($M) ($M)26 kỳ
- International (Legacy Segment Pre-Q2 FY26 Reorg) — Revenue ($M) ($M)24 kỳ
- McKesson Ventures Equity Investments Pre-Tax Net Gains/(Losses) ($M) ($M)10 kỳ
Consolidated Non-GAAP Profitability, Free Cash Flow & Full-Year Guidance Evolution
Customer & Supplier Concentration, Workforce, Opioid Liabilities, LIFO, Leases & Share Repurchases
- Top 10 Customers Share of Consolidated Revenue (%) (%)7 kỳ
- Employees in the United States (Headcount)6 kỳ
- Total Opioid-Related Settlement Liabilities on Balance Sheet ($M) ($M)17 kỳ
- LIFO Inventory Valuation Reserve ($M) ($M)9 kỳ
- Consolidated Long-Lived Assets, Net (Geographic Footnote Total, $M) ($M)10 kỳ
- Operating Lease Right-of-Use (ROU) Assets ($M) ($M)30 kỳ
- Remaining Share Repurchase Authorization ($M) ($M)29 kỳ
U.S. Federal Contract Obligations (USAspending), Pharmaceutical Wholesale Macro (FRED) & Peer Benchmarks
- U.S. Federal Government Prime Contract Obligations to McKesson ($M) ($M)105 kỳ
- U.S. Merchant Wholesalers Sales: Drugs & Druggists' Sundries (NAICS 4242, $M) ($M)103 kỳ
- U.S. Retail Sales: Pharmacies & Drug Stores (NAICS 44611, $M) ($M)104 kỳ
- Peer Benchmark: Cencora, Inc. (COR) — Consolidated Revenue ($M) ($M)25 kỳ
- Peer Benchmark: Cardinal Health, Inc. (CAH) — Consolidated Revenue ($M) ($M)23 kỳ
- Peer Benchmark: Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M) ($M)25 kỳ
Consolidated GAAP Financial Statements & XBRL Segment Baseline
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của McKesson
- McKesson 10-K (filed 2026-05-08, acc 0000927653-26-000069) ↗
- McKesson 10-Q (filed 2026-08-05, acc 0000927653-26-000234) ↗
- McKesson 8-K (filed 2026-08-05, acc 0000927653-26-000232) ↗
- McKesson 8-K (filed 2026-05-07, acc 0000927653-26-000066) ↗
- USAspending.gov Federal Contract Awards — McKesson Corporation ↗
- McKesson Earnings Call Transcript FY2027Q1 ↗
- McKesson Earnings Call Transcript FY2026Q4 ↗
- McKesson 8-K (filed 2025-08-06, acc 0000927653-25-000105) ↗
- McKesson 8-K (filed 2025-05-08, acc 0000927653-25-000034) ↗
- SEC EDGAR XBRL CompanyFacts (COR) ↗
- SEC EDGAR XBRL CompanyFacts (CAH) ↗
- SEC EDGAR XBRL CompanyFacts (OPCH) ↗
See a number that looks wrong?